389 related articles for article (PubMed ID: 27367039)
21. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
Mahon FX; Etienne G
Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
[TBL] [Abstract][Full Text] [Related]
22. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.
Elsayed AG; Srivastava R; Jamil MO
Curr Oncol Rep; 2017 Oct; 19(12):77. PubMed ID: 28988389
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
Shah NP; García-Gutiérrez V; Jiménez-Velasco A; Larson S; Saussele S; Rea D; Mahon FX; Levy MY; Gómez-Casares MT; Pane F; Nicolini FE; Mauro MJ; Sy O; Martin-Regueira P; Lipton JH
Leuk Lymphoma; 2020 Mar; 61(3):650-659. PubMed ID: 31647335
[TBL] [Abstract][Full Text] [Related]
24. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
[TBL] [Abstract][Full Text] [Related]
25. Chronic myeloid leukaemia: Biology and therapy.
Wang Y; Liang ZJ; Gale RP; Liao HZ; Ma J; Gong TJ; Shao YQ; Liang Y
Blood Rev; 2024 May; 65():101196. PubMed ID: 38604819
[TBL] [Abstract][Full Text] [Related]
26. [Chronic myeloid leukemia: aiming for treatment free remission].
Kimura S
Rinsho Ketsueki; 2021; 62(6):572-581. PubMed ID: 34219083
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice.
Clark RE
Curr Hematol Malig Rep; 2019 Dec; 14(6):507-514. PubMed ID: 31701369
[TBL] [Abstract][Full Text] [Related]
28. Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.
Akard LP; Bixby D
Leuk Lymphoma; 2016 May; 57(5):1002-14. PubMed ID: 26726949
[TBL] [Abstract][Full Text] [Related]
29. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
Ross DM; Pagani IS; Shanmuganathan N; Kok CH; Seymour JF; Mills AK; Filshie RJ; Arthur CK; Dang P; Saunders VA; Braley J; Yong AS; Yeung DT; White DL; Grigg AP; Schwarer AP; Branford S; Hughes TP;
Leukemia; 2018 Dec; 32(12):2572-2579. PubMed ID: 30315232
[TBL] [Abstract][Full Text] [Related]
30. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambÈ L; Conticello C; DI Raimondo F; Stagno F
Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
[TBL] [Abstract][Full Text] [Related]
32. Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
Etienne G; Faberes C; Bauduer F; Adiko D; Lifermann F; Dagada C; Lenoir C; Schmitt A; Klein E; Fort MP; Bijou F; Turcq B; Robbesyn F; Durrieu F; Versmée L; Madene S; Moldovan M; Katsahian S; Charles-Nelson A; Lascaux A; Mahon FX; Dulucq S
Cancer Med; 2021 Jun; 10(11):3635-3645. PubMed ID: 33988316
[TBL] [Abstract][Full Text] [Related]
33. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.
Erba HP
Am J Hematol; 2015 Mar; 90(3):242-9. PubMed ID: 25410137
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
35. Prospects for achieving treatment-free remission in chronic myeloid leukaemia.
Saglio G; Gale RP
Br J Haematol; 2020 Aug; 190(3):318-327. PubMed ID: 32057102
[TBL] [Abstract][Full Text] [Related]
36. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.
Quintás-Cardama A; Choi S; Kantarjian H; Jabbour E; Huang X; Cortes J
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):327-334.e8. PubMed ID: 24594142
[TBL] [Abstract][Full Text] [Related]
37. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
Radich JP; Hochhaus A; Masszi T; Hellmann A; Stentoft J; Casares MTG; García-Gutiérrez JV; Conneally E; le Coutre PD; Gattermann N; Martino B; Saussele S; Giles FJ; Ross DM; Aimone P; Li S; Titorenko K; Saglio G
Leukemia; 2021 May; 35(5):1344-1355. PubMed ID: 33707652
[TBL] [Abstract][Full Text] [Related]
38. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
39. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Perusini MA; Novitzky-Basso I; Atenafu EG; Forrest D; Bence-Bruckler I; Savoie L; Keating MM; Busque L; Delage R; Xenocostas A; Liew E; Laneuville P; Paulson K; Stockley T; Lipton JH; Leber B; Kim DDH
Br J Haematol; 2023 Dec; 203(5):781-791. PubMed ID: 37697469
[TBL] [Abstract][Full Text] [Related]
40. When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.
Laneuville P
Curr Treat Options Oncol; 2018 Mar; 19(3):15. PubMed ID: 29520446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
